OR7D2 Inhibitors
OR7D2 inhibitors are a class of chemical compounds designed to modulate the activity of the OR7D2 receptor, which is part of the olfactory receptor family of G-protein-coupled receptors (GPCRs). These receptors are primarily known for their role in the detection of odorants within the olfactory epithelium. OR7D2, like other olfactory receptors, possesses a seven-transmembrane domain structure characteristic of GPCRs, allowing it to interact with specific ligands and transduce signals via G-proteins. Inhibitors targeting OR7D2 aim to prevent the receptor from binding to its natural ligands, thereby modulating the signal transduction pathways initiated by this receptor.
The chemical structures of OR7D2 inhibitors are designed to complement the binding site of the receptor, often featuring aromatic rings and functional groups capable of forming hydrogen bonds or hydrophobic interactions. These molecular characteristics enable the inhibitors to fit into the receptor's active site, blocking the access of natural ligands. The development of OR7D2 inhibitors involves techniques such as molecular docking studies and structure-activity relationship analyses to optimize their affinity and specificity for the receptor. By studying these inhibitors, researchers gain insights into the binding mechanisms and structural requirements necessary for effective modulation of OR7D2, contributing to a deeper understanding of olfactory receptor function and GPCR signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may suppress the transcription of OR7D2 by inhibiting the activity of transcription factors or directly hindering RNA polymerase binding to DNA. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D could bind to the DNA template, leading to a cessation of OR7D2 transcription by obstructing the progression of RNA polymerase. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylase, Trichostatin A can remodel chromatin to a closed conformation, resulting in the decreased transcriptional activity of genes including OR7D2. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may reduce the methylation levels of the OR7D2 gene promoter, potentially leading to a downregulation of its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin can suppress mTOR pathway signaling, which is critical for cap-dependent translation initiation, possibly resulting in reduced synthesis of the OR7D2 protein. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide blocks the translocation step in protein synthesis, which would lead to a decrease in OR7D2 protein levels due to inhibited translation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Alpha-amanitin selectively inhibits RNA polymerase II, which could cause a decline in OR7D2 mRNA levels and subsequent protein expression. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB can halt RNA polymerase II during the elongation phase, potentially leading to a diminished production of OR7D2 transcripts. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to GC-rich sequences in DNA, which could prevent the initiation of OR7D2 transcription, resulting in lower mRNA and protein levels. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone could decrease the expression of OR7D2 by antagonizing aldosterone, which may play a role in the transcriptional control of certain GPCRs. | ||||||